To include your compound in the COVID-19 Resource Center, submit it here.

Therapeutics: MAP kinase 7 (MAPK7; BMK1; ERK-5); mitogen-activated protein kinase kinase kinase 2 (MAP3K2); WNK lysine deficient protein kinase 1 (WNK1; PPP1R16

Cancer

INDICATION: Prostate cancer

Patient sample, mouse and cell culture studies suggest inhibiting MAPK7 or the MAPK7 pathway components MAP3K2 and

Read the full 193 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE